Pharnext presenteert op BIO CEO & Investor Conference 2017
PARIJS–(BUSINESS WIRE)– Pharnext SA (Paris:ALPHA) (FR00111911287 – ALPHA), een Frans biofarmaceutisch bedrijf met een geavanceerd portfolio op gebied van neurodegeneratieve ziekten, heeft vandaag bekendgemaakt dat de directie een zakelijk overzicht geeft op de BIO CEO & Investor Conference 2017.
De presentatie heeft plaatst op:
- Datum: maandag, 13 februari 2017
- Tijd: 10.00 uur ET (16.00 uur CET)
- Locatie: The Waldorf Astoria in New York City, in New York.
Pharnext to Present at 2017 BIO CEO & Investor Conference |
|||||
|
PARIS–(BUSINESS WIRE)– Regulatory News: Pharnext SA (Paris:ALPHA) (FR00111911287 – ALPHA), a French biopharmaceutical company developing an advanced portfolio of products in the field of neurodegenerative diseases, announced today that company management will present a corporate overview at the 2017 BIO CEO & Investor Conference. The presentation will take place as follows:
If you are interested in meeting the Pharnext management team during this event, please send an email to Sarah McCabe at sarah@sternir.com About Pharnext Pharnext is an advanced clinical stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext focuses on neurodegenerative diseases and has two lead products in clinical development: PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer’s disease. Pharnext is the pioneer of a new drug discovery paradigm: PLEOTHERAPY ™. The company identifies and develops synergic combinations of repositioned drugs at low dose. These PLEODRUG ™ offer several key advantages: efficacy, safety, and intellectual property including several composition of matter patents already granted. The Company is supported by a world-class scientific team. The company Pharnext is listed on Euronext Alternext Stock Exchange in Paris (ISIN code: FR00111911287). For more information, visit www.pharnext.com View source version on businesswire.com: http://www.businesswire.com/news/home/20170206006180/en/ Contacts Pharnext |
|||||